LOx offers a new pharmacophoric linking approach, integrated with Scopius, the largest available curated 3D compound and fragment database
Oxford, UK, October 28th, 2010. InhibOx Ltd today announces LOx 2.0 - a flexible new system to identify and optimize drug lead candidates through preserving and linking critical features with new scaffolds. Lox 2.0 carries fragment-linking tools a stage further and delivers a powerful approach for drug discovery scientists seeking to alter the core scaffold of a lead series to maximize activity, optimize physical properties and to create novel intellectual property.
